Vanguard Group’s PAVmed PAVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $75.6K | Buy |
11,406
+4,460
| +64% | +$50.9K | ﹤0.01% | 4200 |
|
|
2025
Q3 | $90.2K | Buy |
6,946
+4,230
| +156% | +$62.9K | ﹤0.01% | 4236 |
|
|
2025
Q2 | $48.9K | Hold |
2,716
| – | – | ﹤0.01% | 4200 |
|
|
2025
Q1 | $58.8K | Hold |
2,716
| – | – | ﹤0.01% | 4180 |
|
|
2024
Q4 | $51.2K | Sell |
2,716
-6,651
| -71% | -$197K | ﹤0.01% | 4212 |
|
|
2024
Q3 | $346K | Sell |
9,367
-479
| -5% | -$14.7K | ﹤0.01% | 4052 |
|
|
2024
Q2 | $241K | Sell |
9,846
-172
| -2% | -$8.58K | ﹤0.01% | 4139 |
|
|
2024
Q1 | $643K | Sell |
10,018
-69
| -0.7% | -$5.22K | ﹤0.01% | 3952 |
|
|
2023
Q4 | $1.25M | Buy |
10,087
+1,628
| +19% | +$192K | ﹤0.01% | 3753 |
|
|
2023
Q3 | $1.12M | Buy |
8,459
+231
| +3% | +$35.8K | ﹤0.01% | 3794 |
|
|
2023
Q2 | $1.51M | Hold |
8,228
| – | – | ﹤0.01% | 3758 |
|
|
2023
Q1 | $1.38M | Hold |
8,228
| – | – | ﹤0.01% | 3808 |
|
|
2022
Q4 | $1.78M | Buy |
8,228
+4
| +0% | +$1.51K | ﹤0.01% | 3710 |
|
|
2022
Q3 | $3.18M | Buy |
8,224
+525
| +7% | +$298K | ﹤0.01% | 3551 |
|
|
2022
Q2 | $3.24M | Sell |
7,699
-1,672
| -18% | -$808K | ﹤0.01% | 3588 |
|
|
2022
Q1 | $5.57M | Buy |
9,371
+260
| +3% | +$193K | ﹤0.01% | 3476 |
|
|
2021
Q4 | $10.1M | Sell |
9,111
-142
| -2% | -$309K | ﹤0.01% | 3197 |
|
|
2021
Q3 | $35.6M | Buy |
9,253
+282
| +3% | +$889K | ﹤0.01% | 2547 |
|
|
2021
Q2 | $25.8M | Buy |
8,971
+1,276
| +17% | +$3.01M | ﹤0.01% | 2715 |
|
|
2021
Q1 | $15.4M | Buy |
7,695
+2,620
| +52% | +$3.94M | ﹤0.01% | 2931 |
|
|
2020
Q4 | $4.84M | Buy |
5,075
+1,426
| +39% | +$1.22M | ﹤0.01% | 3375 |
|
|
2020
Q3 | $2.92M | Sell |
3,649
-203
| -5% | -$181K | ﹤0.01% | 3378 |
|
|
2020
Q2 | $3.66M | Buy |
3,852
+741
| +24% | +$741K | ﹤0.01% | 3236 |
|
|
2020
Q1 | $2.77M | Buy |
3,111
+141
| +5% | +$115K | ﹤0.01% | 3208 |
|
|
2019
Q4 | $1.6M | Sell |
2,970
-7
| -0.2% | -$2.92K | ﹤0.01% | 3508 |
|
|
2019
Q3 | $1.28M | Buy |
2,977
+480
| +19% | +$219K | ﹤0.01% | 3575 |
|
|
2019
Q2 | $1.28M | Buy |
2,497
+1,587
| +174% | +$839K | ﹤0.01% | 3599 |
|
|
2019
Q1 | $450K | Buy |
910
+34
| +4% | +$15.6K | ﹤0.01% | 3792 |
|
|
2018
Q4 | $379K | Buy |
876
+52
| +6% | +$25.5K | ﹤0.01% | 3789 |
|
|
2018
Q3 | $482K | Buy |
824
+612
| +289% | +$373K | ﹤0.01% | 3859 |
|
|
2018
Q2 | $90K | Buy |
212
+75
| +55% | +$45.9K | ﹤0.01% | 4061 |
|
|
2018
Q1 | $101K | Buy |
+137
| New | +$117K | ﹤0.01% | 4029 |
|
Other funds holding PAVM
GCP
XT
Vanguard Group's PAVM Position: Q4 2025 in Review
Vanguard Group increased its PAVmed (PAVM) stake by 64% in Q4 2025, buying an estimated $50.9K and bringing the position to 11,406 shares worth $75.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4200.
Vanguard Group first reported a position in PAVM in Q1 2018 and has held it in 32 quarters since. The position peaked at $35.6M in Q3 2021. 28 funds tracked by Wall St. Rank hold PAVM as of Q4 2025.
- Vanguard Group held 11,406 shares of PAVmed worth $75.6K as of Q4 2025.
- Vanguard Group bought 4,460 PAVmed shares in Q4 2025, an estimated $50.9K.
- PAVmed made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4200 holding.
- Vanguard Group first reported a position in PAVmed in Q1 2018 and has held it in 32 quarters since.
- Vanguard Group's PAVmed position peaked at $35.6M in Q3 2021.
- 28 funds tracked by Wall St. Rank held PAVmed as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.